Back

Incidence of erythrocytosis and thromboembolic risk in patients with heart failure and reduced ejection fraction treated with SGLT2 Inhibitors

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Advances in cardiovascular pharmacotherapy Antidiabetic Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Abdullahi Ahmed Mohamed

Herlev and Gentofte Hospital, Copenhagen (Denmark)

5 More presentations in this session

Presentation thumbnail
Intravenous loop diuretic-induced decongestion in heart failure: an explorative study in a real-world population
Mr M. Erhardsson (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of sotagliflozin in patients with symptomatic obstructive and non-obstructive hypertrophic cardiomyopathy (SONATA-HCM): study design
Professor I. Olivotto (Florence, IT)
Abstract Slides Video
Presentation thumbnail
The impact of early SGLT2i inclusion in quadruple therapy for de novo patients: enhancing medication management and clinical outcomes
Doctor A. Esteban Fernandez (Leganes, ES)
Abstract Slides Video
Presentation thumbnail
Assessing the best anticoagulation strategy for left ventricle thrombus after anterior myocardial infarction
Doctor F. Rodrigues Santos (Viseu, PT)
Abstract Slides Video
Presentation thumbnail
Direct oral anticoagulants in patients with heart failure and atrial fibrillation: do we have an ideal score to predict major bleeding?
Doctor V. De Simone (Legnago, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Advances in cardiovascular pharmacotherapy

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Secondary erythrocytosis / polycythemia due to sodium glucose co-transporter 2 inhibitors: a real world heart failure cohort.
thumbnail
Congress Presentation
Potential hematopoietic effects of SGLT2 inhibitors in patients with cardiac amyloidosis.
thumbnail
Congress Presentation
Empagliflozin versus dapagliflozin in heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources